Results 11 to 20 of about 21,592 (229)

Alendronate reduces periosteal microperfusion in vivo [PDF]

open access: yesHeliyon, 2023
Objectives: Bisphosphonates are known to induce a severe adverse effect known as medication-related osteonecrosis of the jaw (MRONJ). Previous studies have proven the impact of bisphosphonates on microperfusion; therefore, this study aimed to investigate
Danielle N. Kundert   +6 more
doaj   +2 more sources

The Effect of Once-Weekly 70 Mg Alendronate Versus Once-Daily 10 Mg Alendronate in the Treatment of Postmenopausal Osteoporosis [PDF]

open access: yesTürk Osteoporoz Dergisi, 2004
The aim of this study was to compare the effect of once-weekly 70 mg alendronate versus once-daily 10 mg alendronate in the treatment of postmenopausal osteoporosis. Sixty-three women with postmenopausal osteoporosis were randomly assigned to two groups.
İlker Çorapçı   +4 more
doaj   +1 more source

Evaluation of an aminobisphosphonate (alendronate) in the management of periodontal osseous defects

open access: yesJournal of Indian Society of Periodontology, 2010
Background and Objectives: Alendronate, an aminobisphosphonate, is capable of inhibiting periodontitis associated osteoclastic activity and hence is effective in protecting the alveolar bone in periodontitis.
Veena H, Prasad Deepak
doaj   +2 more sources

Two Years of Alendronate and Calcitonin Treatments for Osteoporosis in Postmenopausal Women - Original Investigation

open access: yesTürk Osteoporoz Dergisi, 2006
This study was to compare and research the effects of alendronate and calcitonin treatments with 2 years duration in women with postmenopausal osteoporosis.
Gülcan Gürer   +3 more
doaj   +1 more source

Duration and timing of bisphosphonate treatment as factors determining osteoblast mineralization

open access: yesJournal of Oral Biology and Craniofacial Research, 2022
Background: Alendronate is a drug for the treatment of excessive bone resorption. Alendronate reduces osteoblast viability and mineralization in a dose-dependent manner. Other views of alendronate could affect mineralization.
Somying Patntirapong
doaj   +1 more source

Alendronate reduced peri-tunnel bone loss and enhanced tendon graft to bone tunnel healing in anterior cruciate ligament reconstruction [PDF]

open access: yesEuropean Cells & Materials, 2013
Peri-tunnel bone loss after anterior cruciate ligament (ACL) reconstruction is commonly observed, both clinically and experimentally. We aimed to study the effect and mechanisms of different doses of alendronate in the reduction of peri-tunnel bone loss ...
PPY Lui   +4 more
doaj   +2 more sources

Impairment of cold injury-induced muscle regeneration in mice receiving a combination of bone fracture and alendronate treatment. [PDF]

open access: yesPLoS ONE, 2017
Alendronate, a nitrogen-containing bisphosphonate, is well established as a treatment for osteoporosis through regulation of osteoclast activity. Previously, the pharmacological effects of bisphosphonates on cells outside the bone environment have been ...
Shigeo Kawada   +2 more
doaj   +1 more source

The Early Effect of Alendronate, Hop Extract and Their Combination on Bone Structural Properties in a Rat Model of Osteoporosis. [PDF]

open access: yesMed Sci (Basel)
Background/Objectives: New approaches using plant-based extracts are increasingly investigated for osteoporosis treatment, including hop extract, which contains potent compounds that favorably affect bone quality.
Rođak E   +5 more
europepmc   +2 more sources

Nickel alendronate [PDF]

open access: yesActa Crystallographica Section E Structure Reports Online, 2012
The title compound {systematic name: bis(μ2-dihydrogen 4-azaniumyl-1-hydroxybutane-1,1-diphosphonato)bis[aqua(dihydrogen 4-azaniumyl-1-hydroxybutane-1,1-diphosphonato)nickel(II)] dihydrate}, [Ni2(C4H12NO7P2)4(H2O)2]·2H2O, was synthesiized under hydrothermal conditions. Its structure is isotypic with the CoII analogue.
Małgorzata Sikorska   +2 more
openaire   +3 more sources

Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine

open access: yesBMC Women's Health, 2022
Background Postmenopausal women compliance to alendronate therapy is suboptimal due to the complex dosing requirements. The poor compliance may increase their potential of fractures and the prevalence of side effects.
Asma Radwan   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy